Literature DB >> 17453824

Ethical and design issues of phase I clinical trials in cancer patients.

Hans W Grünwald1.   

Abstract

Therapeutic clinical trials are an absolute necessity to enhance the therapy of serious illnesses, and Phase I trials are the only way to introduce new therapeutic modalities into use in human beings. However, since the first obligation a physician has is to the individual patient's well-being and avoidance of doing harm, offering such patients an unproven therapy with low probability of benefit to him/herself and significant potential toxicities poses major ethical problems. These ethical problems can only be solved by full disclosure of all facts to the patient, a detailed explanation that the primary goal of the trial is to improve medical care (altruistic motivation), and by making sure that in addition to the trial mandated treatment the patient receives optimal palliative care, including hospice care when needed.

Entities:  

Mesh:

Year:  2007        PMID: 17453824     DOI: 10.1080/07357900701225331

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  5 in total

1.  Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics.

Authors:  Nicolas Penel; Jean-Pierre Delord; Marie-Edith Bonneterre; Thomas Bachelot; Isabelle Ray-Coquard; Jean-Yves Blay; Laurent Benjamin Pascal; Cécile Borel; Thomas Filleron; Antoine Adenis; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2009-02-10       Impact factor: 3.850

2.  Performing nondiagnostic research biopsies in irradiated tissue: a review of scientific, clinical, and ethical considerations.

Authors:  Aaron P Brown; David S Wendler; Kevin A Camphausen; Franklin G Miller; Deborah Citrin
Journal:  J Clin Oncol       Date:  2008-08-20       Impact factor: 44.544

Review 3.  Phase I trials as valid therapeutic options for patients with cancer.

Authors:  Jacob J Adashek; Patricia M LoRusso; David S Hong; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2019-09-02       Impact factor: 66.675

4.  Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trials.

Authors:  Charles Ferte; Jean-Charles Soria; Nicolas Penel
Journal:  PLoS One       Date:  2011-03-02       Impact factor: 3.240

5.  Nature and subjectivity of dose-limiting toxicities in contemporary phase 1 trials: comparison of cytotoxic versus non-cytotoxic drugs.

Authors:  Nicolas Penel; Antoine Adenis; Stéphanie Clisant; Jacques Bonneterre
Journal:  Invest New Drugs       Date:  2010-07-09       Impact factor: 3.651

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.